NR4A1 and breast carcinoma: While chemotherapy remains a foundational option in the first-line setting—especially in advanced stages—the use of maintenance hormonal therapy is increasingly supported across guidelines, mirroring treatment strategies seen in hormone receptor–positive breast cancer.